Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles
· Early and confirmed anti-tumor activity, 16 of 20 patients with disease control at first scan and sustained tumor control for 13 of 18 patients with >3 months follow-up · Durable clinical benefit, median time to progression (to date) ~4.5 months with >50% of patients still on treatment · Consistently good safety and tolerability profile Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that all patients in the ongoing phase 2a study in